Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics reported Q2 revenue of $99.3 million, up 66% year-over-year, driven by sales of Amtagvi, its FDA-approved cancer treatment. The company narrowed its net loss to $47.3 million from $111.7 million in the prior-year quarter, signaling improving unit economics as the commercial launch gains traction.

Amtagvi, a tumor-infiltrating lymphocyte therapy approved for advanced melanoma, is delivering the bulk of the revenue growth in its first full quarters on the market. The sequential acceleration and steep loss reduction suggest the company is managing cash burn while scaling distribution. Analysts cited in the source view Amtagvi as having blockbuster potential, though they noted current valuation concerns as the stock rallied on the print.

The stock moved sharply higher following the release, reflecting investor confidence in the commercial trajectory and the narrowing path to profitability. The company has not yet provided formal break-even guidance, but the year-over-year improvement in losses at 58% sets a bullish baseline for the second half.